CRMD Share Price Performance
US$10.08
-0.41 (-3.91%)
50.6% undervalued intrinsic discount
US$20.40
Fair Value
Price US$10.08
AnalystConsensusTarget US$20.40
Fair ValueUS$20.40
Share PriceUS$10.08
50.6% undervalued intrinsic discount
CorMedix Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 61 Fair Values set on narratives written by author
CRMD Community Narratives
AN
Fair Value US$20.4 50.6% undervalued intrinsic discount
Acquisition And Pipeline Expansion Will Unlock Healthcare Potential
0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
Acquisition And Pipeline Expansion Will Unlock Healthcare Potential
Key Takeaways Acquisition and integration efforts diversify revenue streams and improve operational efficiency, supporting stronger earnings and margin growth. Expanded pipeline and portfolio address rising demand in infection control, enhancing market penetration and supporting long-term profitability.
0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
AN
US$20.4
50.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
52.83% p.a.
Profit Margin
56.43%
Future PE
9.24x
Share price in 2028
US$16.26
Snowflake Analysis
CorMedix Inc. Key Details
About CRMD
- Founded
- 2006
- Employees
- 65
- CEO
- WebsiteView website
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
